TY - JOUR
T1 - Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting
AU - Ye, Fei
AU - Feldman, Darren R.
AU - Valentino, Alisa
AU - So, Rachel
AU - Bromberg, Maria
AU - Khan, Shah
AU - Funt, Samuel A.
AU - Sheinfeld, Joel
AU - Solit, David B.
AU - Pessin, Melissa S.
AU - Peerschke, Ellinor I.
N1 - Funding Information:
Supported in part by the Department of Laboratory Medicine (E.I.P.), the Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (D.B.S.), Cycle for Survival (D.R.F.), and the NIH / National Cancer Institute Cancer Center Support grant P30 CA008748 .
Funding Information:
Supported in part by the Department of Laboratory Medicine (E.I.P.), the Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (D.B.S.), Cycle for Survival (D.R.F.), and the NIH/National Cancer Institute Cancer Center Support grant P30 CA008748.Disclosures: D.B.S. has consulted for/received honoraria from Pfizer, Loxo/Lilly Oncology, Vividion Therapeutics, FORE Therapeutics, Scorpion Therapeutics, and BridgeBio. S.A.F. receives research funding from AstraZeneca and Genetech/Roche, has consulted for/received honoraria from Merck, and has stock/equity ownership in Allogene Therapeutics, Urogen, Kronos Bio, Neogene Therapeutics, IconOVir, and Vida Ventures. The other authors declare no conflicts of interest.
Publisher Copyright:
© 2022 Association for Molecular Pathology and American Society for Investigative Pathology
PY - 2022/8
Y1 - 2022/8
N2 - Detection of serum embryonic miRNAs miR-371a-3p and miR-372-3p has been proposed to aid in diagnosis, prognosis, and management of patients with testicular germ cell tumors (GCTs). This study describes the analytical validation and performance of a laboratory-developed test to detect these miRNA targets by stem loop real-time quantitative RT-PCR (RT-qPCR) in serum from patients with GCTs. The assay was standardized using an exogenous spike-in control of nonhuman miRNA from Caenorhabditis elegans (cel-miR-39-3p) to assess extraction efficiency, and an endogenous housekeeping miRNA, miR-30b-5p, to control for miRNA normalization. miRNA results were expressed as relative expression level, using the comparative threshold cycle method (2ΔΔCT). Analytical sensitivity of miR-371a-3p and miR-372-3p was 12.5 and 1.25 copies/μL, respectively. Clinical accuracy was evaluated using GCT patients with (n = 34) and without (n = 17) active disease. Positive/negative cutoffs and indeterminate findings were established on the basis of results from healthy volunteers (n = 25) and assay precision. miR-371a-3p and miR-372-3p exhibited a sensitivity of 81.8% and 87.5%, respectively, and a specificity of 100% and 94%, respectively, and an area under the receiver operating characteristic curve of 0.93 and 0.95, respectively. Taken together, RT-qPCR testing for serum miR-371a-3p and miR-372-3p represents a robust, sensitive, and specific clinical assay to aid in the clinical management of patients with GCT.
AB - Detection of serum embryonic miRNAs miR-371a-3p and miR-372-3p has been proposed to aid in diagnosis, prognosis, and management of patients with testicular germ cell tumors (GCTs). This study describes the analytical validation and performance of a laboratory-developed test to detect these miRNA targets by stem loop real-time quantitative RT-PCR (RT-qPCR) in serum from patients with GCTs. The assay was standardized using an exogenous spike-in control of nonhuman miRNA from Caenorhabditis elegans (cel-miR-39-3p) to assess extraction efficiency, and an endogenous housekeeping miRNA, miR-30b-5p, to control for miRNA normalization. miRNA results were expressed as relative expression level, using the comparative threshold cycle method (2ΔΔCT). Analytical sensitivity of miR-371a-3p and miR-372-3p was 12.5 and 1.25 copies/μL, respectively. Clinical accuracy was evaluated using GCT patients with (n = 34) and without (n = 17) active disease. Positive/negative cutoffs and indeterminate findings were established on the basis of results from healthy volunteers (n = 25) and assay precision. miR-371a-3p and miR-372-3p exhibited a sensitivity of 81.8% and 87.5%, respectively, and a specificity of 100% and 94%, respectively, and an area under the receiver operating characteristic curve of 0.93 and 0.95, respectively. Taken together, RT-qPCR testing for serum miR-371a-3p and miR-372-3p represents a robust, sensitive, and specific clinical assay to aid in the clinical management of patients with GCT.
UR - http://www.scopus.com/inward/record.url?scp=85135549912&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2022.04.007
DO - 10.1016/j.jmoldx.2022.04.007
M3 - Article
C2 - 35934321
AN - SCOPUS:85135549912
VL - 24
SP - 867
EP - 877
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
SN - 1525-1578
IS - 8
ER -